46th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100292184 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE - The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO | 2010-11-18 |
20100292185 | BETA-LACTAMASE INHIBITORS - Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof. | 2010-11-18 |
20100292186 | Pharmaceutical Composition for Treatment or Prevention of Liver Cancer - An object of the present invention is to provide an excellent liver cancer treatment agent or prevention agent. The present invention provides a pharmaceutical composition for treating or preventing liver cancer, comprising menatetrenone, which is one species of vitamin K, and a phospholipid, said phospholipid being preferably egg yolk lecithin or soybean lecithin. | 2010-11-18 |
20100292187 | METHODS FOR TREATING HEPATITIS C - The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity. | 2010-11-18 |
20100292188 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals. | 2010-11-18 |
20100292189 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS - A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5′ and 3′ cyclization sequences. | 2010-11-18 |
20100292190 | NOVEL TUBULIN POLYMERISATION INHIBITORS - The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds. | 2010-11-18 |
20100292191 | Alkylene Oxide Adducts of Oligosaccharides - The invention is related to alkylene oxide adducts of oligosaccharides, obtained by a process comprising alkoxylating at least one water-soluble oligosaccharide in aqueous solution at a temperature in the range of 90 to 160° C. The compounds are useful as adjuvants in agrochemical compositions. | 2010-11-18 |
20100292192 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2010-11-18 |
20100292193 | RADIOPROTECTIVE DRUGS - Drugs and their compositions useful in preventing and treating negative side effects associated with radiation exposure or clinical radiotherapy are disclosed. More specifically, new compounds that can be administered systemically to patients exposed to radiation or undergoing radiotherapy and methods of using these formulations are disclosed. | 2010-11-18 |
20100292194 | FORMULAS COMPRISING HIGHLY SOLUBLE ELEMENTS AND VITAMINS FOR THE PREVENTION AND AMELIORATION OF OSTEOPOROSIS - The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D | 2010-11-18 |
20100292195 | LOW BURST POLYMERS AND METHODS TO PRODUCE POLYMER - A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use. | 2010-11-18 |
20100292196 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided. | 2010-11-18 |
20100292197 | Compositions and Methods for Increasing Telomerase Activity - The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells. | 2010-11-18 |
20100292198 | CYCLIC PROGESTIN REGIMENS AND KITS - A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen. | 2010-11-18 |
20100292199 | TRANSCUTANEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING A STEROID HORMONE - The present invention concerns aqueous-alcoholic, single-phase transcutaneous pharmaceutical compositions with an amount of alcohol of greater than 30% containing a steroid hormone combined with at least one penetrating agent selected from propylene glycol fatty acid esters, terpene derivatives, and mixtures thereof. | 2010-11-18 |
20100292200 | Methods for Modulating Apoptosis in Platelets - The description discloses methods of enhancing or maintaining the viability or lifespan of platelets comprising administering an agent that down modulates apoptosis. The description also discloses a method of decreasing the survival, lifespan or viability of platelets comprising administering an effective amount of an agent that enhances apoptosis. | 2010-11-18 |
20100292201 | NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL - The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity. | 2010-11-18 |
20100292202 | FUNGICIDAL COMPOSITIONS FOR TURF TREATMENT AND IMPROVEMENT - The present invention relates to novel compositions comprising a fungicide that inhibits mitochondrial respiration at the QoI site, (QoI inhibitor), a contact fungicide, a demethylation inhibitor and pigments, which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the fungicidal compositions are able to control mold and fungus infection in grasses, in particular turf grasses. | 2010-11-18 |
20100292203 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2010-11-18 |
20100292204 | SULPHUR CONTAINING PYRAZOLE DERIVATIVES AS SELECTIVE CANNABINOID CB1 RECEPTOR ANTAGONISTS - The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB | 2010-11-18 |
20100292205 | Pyrimidone Compounds As GSK-3 Inhibitors - The invention pertains to pyrimidone compounds that serve as effective GSK-3 inhibitors. The invention further relates to pharmaceutical compositions and methods comprising such pyrimidone compounds; and the use of such compounds for treating certain disorders. | 2010-11-18 |
20100292206 | HETEROCYCLIC COMPOUND - The present invention relates to | 2010-11-18 |
20100292207 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. | 2010-11-18 |
20100292208 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE - Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene A | 2010-11-18 |
20100292209 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE NEUROTROPHIC FACTOR SIGNALING - The invention relates to screening for compounds and compositions that modulate neurotrophic factor signaling as reflected by modulation of factor-induced neurite outgrowth. The compounds and compositions are useful in the treatment of a variety of disorders. The invention also provides methods for preparing compounds for treatment of such disorders. | 2010-11-18 |
20100292210 | Novel Compounds for A-Beta-Related Pathologies - The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with γ-secretase and/or its substrate and hence modulate the formation of Aβ peptides. | 2010-11-18 |
20100292211 | ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE - The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction. | 2010-11-18 |
20100292212 | NEW AZACYCLIC DERIVATIVES - The present invention relates to compounds of formula (I) | 2010-11-18 |
20100292213 | Anti-Inflammatory Agents - The invention provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder: | 2010-11-18 |
20100292214 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans - The Invention relates to compounds having an antiparasitic activity, and to their use as a drug, in particular as a drug for the prevention and/or treatment of parasitic diseases caused by apicomplexans. The invention also relates to pharmaceutical compositions containing those compounds. | 2010-11-18 |
20100292215 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS - A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. | 2010-11-18 |
20100292216 | Methods and Compositions for the Treatment of Psychiatric Conditions - This invention relates to methods and compositions for treating psychiatric conditions, such as depression. | 2010-11-18 |
20100292217 | RANOLAZINE FOR THE TREATMENT OF CNS DISORDERS - The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine. | 2010-11-18 |
20100292218 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives - The present invention provides compounds of formulae Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va and the therapeutic use thereof. The present invention also includes methods of treating NF2-deficient or NF1-deficient cells or neurodegenerative diseases with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. Furthermore, the present invention is directed to methods of inhibiting the growth of NF2-deficient or NF1-deficient tumors. The methods comprise contacting NF2-deficient or NF1-deficient tumor cells with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. The present invention is also directed to the combinational use of radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va with at least one additional active agent, such as one or more HSP90 inhibitors. | 2010-11-18 |
20100292219 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION - The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R | 2010-11-18 |
20100292220 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 2010-11-18 |
20100292221 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 2010-11-18 |
20100292222 | CHEMICAL COMPOUNDS 751 - The invention concerns bicyclic compounds of Formula (I) | 2010-11-18 |
20100292223 | INDAZOLE-CARBOXAMIDE COMPOUNDS - The invention provides novel indazole-carboxamide 5-HT | 2010-11-18 |
20100292224 | ISOTHIAZOLIDINE 1,1-DIOXIDE AND TETRAHYDRO-2H-1,2-THIAZINE 1,1-DIOXIDE DERIVATIVES AS P2X7 MODULATORS - The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof:
| 2010-11-18 |
20100292225 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula I; | 2010-11-18 |
20100292226 | Active Compound Combinations Having Insecticidal Properties - The invention relates to novel insecticidal active compound combinations comprising, firstly, anthranilamides and, secondly, further insecticidally active compounds as defined in the description, which combinations are highly suitable for controlling animal pests, such as insects. | 2010-11-18 |
20100292227 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of formula I: | 2010-11-18 |
20100292228 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS - This invention concerns substituted oxa-diaza-spiro-[5.5]-undecanone derivatives having neurokinin antagonistic activity, in particular an NK | 2010-11-18 |
20100292229 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES - The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis. | 2010-11-18 |
20100292230 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders - The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. | 2010-11-18 |
20100292231 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers - Compounds of formula (I) or formula (Ia) and a method of treating a patient suffering from certain inflammatory disorders, demyelinating disorders, FLT3-mediated disorders, CSF-1R-mediated disorders, cancers and leukemias, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof. | 2010-11-18 |
20100292232 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS - Disclosed herein are antiviral agents, in particular non-nucleoside reverse transcriptase inhibitors (NNRTIs) of the formula | 2010-11-18 |
20100292233 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS - The present invention relates to certain (1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, sepsis, myocardial infarction, ischemic stroke, acne, microbial infections or diseases and viral infections or diseases. | 2010-11-18 |
20100292234 | TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF - The present invention comprises a new class of compounds useful for modulating the activity of p38 MAP kinase. The compounds have a general Formula I | 2010-11-18 |
20100292235 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof - Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: | 2010-11-18 |
20100292236 | 5-Membered Heterocyclic Amides And Related Compounds - 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | 2010-11-18 |
20100292237 | Method for Combating Phytopathogenic Fungi - The present invention relates to the use of an active compound that inhibits the mitochondrial breathing chain at the level of the b/c | 2010-11-18 |
20100292238 | Phenoxymethyl Heterocyclic Compounds - Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof. | 2010-11-18 |
20100292239 | NOVEL MICROBIOCIDES - Compounds of the formula (I), in which the substituents are as defined in claim | 2010-11-18 |
20100292240 | SULFONAMIDE COMPOUNDS - Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases. | 2010-11-18 |
20100292241 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES - The present invention is directed to 3,5-disubstituted-1,3-oxazolidin-2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neuro-ological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2010-11-18 |
20100292242 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF - Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention. | 2010-11-18 |
20100292243 | 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETR- AHYDROISOQUINOLINE AND USE THEREOF - Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention. | 2010-11-18 |
20100292244 | HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR - The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer. | 2010-11-18 |
20100292245 | (EN) SUBSTITUTED 2-AMINO-3-SULFONYL-PYRAZOLO[1,5-A] PYRIMIDINES/ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF - The present invention relates to novel substituted 2-amino-3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines of general formula 1, to serotonin 5-HT | 2010-11-18 |
20100292246 | FORMULATIONS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL- )-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE - The instant invention provides formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione; processes for the production of such formulations; and methods of treating HIV or AIDS with such crystalline materials or such formulations. | 2010-11-18 |
20100292247 | HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS - Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. | 2010-11-18 |
20100292248 | COMBINATION PREPARATIONS COMPRISING SLV308 AND A DOPAMINE AGONIST - A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: | 2010-11-18 |
20100292249 | MANUFACTURE OF RIMCAZOLE - The present invention relates to a process for preparing Rimcazole and its salts. | 2010-11-18 |
20100292250 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- - TETRAHYDROISOQUINOLINE AND USE THEREOF - Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention. | 2010-11-18 |
20100292251 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF - The invention relates to Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III). Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III) for the preparation of substantially pure [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid or its alkali salts and pharmaceutical composition comprising the same. | 2010-11-18 |
20100292252 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2010-11-18 |
20100292253 | PESTICIDAL COMPOSITIONS - This document discloses molecules having the following formula (“Formula I”): | 2010-11-18 |
20100292254 | Fused Pyrimidine Derivatives as Trpv3 Modulators - The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein. | 2010-11-18 |
20100292255 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders - The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer. | 2010-11-18 |
20100292256 | (EN) 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO [1,5-A]PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF - The invention relates to substituted 2-alkylamino-3-(arylsulfonyl)cycloalkyl[e or d]pyrazolo[1,5-a]pyrimidines, to serotonin 5-HT | 2010-11-18 |
20100292257 | USES OF 2-[PIPERIDINYL] METHYL-2, 3-DIHYDROIMIDAZO [1,2-C] QUINAZOLIN-5 (6H)-ONE FOR PROVIDING AN ANALGESIC EFFECT, ANTI-ALLERGIC EFFECT AND HISTAMINE H1 RECEPTOR ANTAGONISM EFFECT - The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H | 2010-11-18 |
20100292258 | SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDS AS FUNGICIDES - The present invention relates to compounds of formula (I) wherein R | 2010-11-18 |
20100292259 | PYRIMIDYL INDOLINE COMPOUND - It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof: | 2010-11-18 |
20100292260 | 6-VINYL PYRIMIDINE AND PYRIMIDINONE DERIVATIVES AND THE USE THEREOF - The invention relates to 6-vinyl pyrimidine pyrimidinone derivatives and the use thereof as medicaments in particular for the treatment of HTV infections, the use thereof for preparing pharmaceutical compositions and methods for the preparation thereof. | 2010-11-18 |
20100292261 | QUORUM SENSING ANTAGONIST, METHOD OF PREVENTING A BIOFILM FORMATION USING THE QUORUM SENSING ANTAGONIST AND METHOD OF REDUCING A BACTERIAL CONTAMINATION USING THE QUORUM SENSING ANTAGONIST - In the quorum sensing antagonist blocking the communication in bacteria, the method for preventing biofilm formation using this quorum sensing antagonist and the method for reducing the bacterial contamination, the quorum sensing antagonist contains the homoserine lactone moiety and sulfanylethanoyl group, and has a similar chemical structure to that of the autoinducer which is produced by bacteria as a signal, whereby the quorum sensing antagonist can inhibit the formation of biofilm and reduce the bacterial contamination as well. | 2010-11-18 |
20100292262 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES - Compounds of the formula (I), in which R | 2010-11-18 |
20100292263 | CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS - Compounds of formula I: | 2010-11-18 |
20100292264 | Small molecules with antiprotozoal activity - The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria. | 2010-11-18 |
20100292265 | Pack Of Medicinal Tablets - A water- and oxygen-occlusive pack is described. The pack encloses an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof. | 2010-11-18 |
20100292266 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase - Certain oxazolyl piperidine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 2010-11-18 |
20100292267 | PALONOSETRON FREE BASE AND PROCESS FOR ITS PREPARATION - The present invention provides novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation. The present invention also provides a process for the preparation of palonosetron hydrochloride from the novel palonosetron free base in an amorphous form and/or in crystalline form-G. | 2010-11-18 |
20100292268 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 2010-11-18 |
20100292269 | BIR DOMAIN BINDING COMPOUNDS - The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: | 2010-11-18 |
20100292270 | TREATMENT OF CACHEXIA - The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose. | 2010-11-18 |
20100292271 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor - The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin | 2010-11-18 |
20100292272 | SUPRAMOLECULAR CO-COLLOIDS PRODUCED USING MACROCYCLIC POLYANIONIC SYSTEMS - The present invention relates to a method preparing co-colloidal dispersions of active hydrophobic substances, such as pharmaceutical products, products having cosmetic properties or any other chemical product. The co-colloidal dispersions thus obtained are characterized in that they are formed by amphiphilic complexes resulting from combinations by non-covalent bonds between a hydrophobic active substance and a suitable hydrophilic molecule. | 2010-11-18 |
20100292273 | Cannabinoid Receptor Modulators - Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from —C(R | 2010-11-18 |
20100292274 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS - A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses. | 2010-11-18 |
20100292275 | FUNGICIDAL HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2010-11-18 |
20100292276 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS - The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold, anxiety and depression. | 2010-11-18 |
20100292277 | COMBINATION TREATMENT OF METABOLIC DISORDERS - Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a combination of a direct PPAR-gamma agonist and a Compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) Three of R | 2010-11-18 |
20100292278 | Methods of treating vascular disease and injury - The present invention provides a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a compound or composition that down-regulates or decreases the activity of microRNA-29 in the individual. Also provided is a method of down-regulating or decreasing the activity of microRNA-29 in an individual in need of such treatment, comprising the step of administering a PPAR-γ agonist compound or PPAR-γ agonist containing composition that down-regulates or decreases the activity of microRNA-29 in the individual. Further provided is a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a microRNA-29 antagonist that down-regulates or decreases the activity of microRNA-29 in said individual. | 2010-11-18 |
20100292279 | Bis-(Sulfonylamino) Derivatives in Therapy - The invention provides compounds of formula | 2010-11-18 |
20100292280 | ANTI-PYRETIC VASODILATORS - The invention provides vasodilating medication as means for lowering fever when administered to humans in need of such treatment. In particular, the use of B3 vitamin substances and Nitric Oxide-donor ingredients in compositions intended for use in reducing fever is introduced. The core composition substances can be used effectively on their own. Yet, in combination with anti-pyretic substances such as Aspirin, Acetaminophen, and Ibuprofen, the present invention enables the use of reduced dosage of composing substances for achievement of desired fever reduction effect. In addition, an optional addition of sweat inducing plant extracts in any of the noted compositions leads to a synergistic effect of reducing fever by increase of both skin blood flow and perspiration. | 2010-11-18 |
20100292281 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE - The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof. | 2010-11-18 |
20100292282 | SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST - The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof. | 2010-11-18 |
20100292283 | NOVEL PHENYL-ACETAMIDE AND PHENYL-PROPIONAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel phenyl-acetamide and phenyl-propionamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels. | 2010-11-18 |